Vol 7, No 2 (2011)

March/April

Open Access Open Access  Restricted Access Subscription or Fee Access

Table of Contents

Letters to the Editor

Tapentadol: An initial analysis—follow-up
Tanya Nelson, PharmD, Vincent Brett, MS, RPh, Eric Prommer, MD
PDF
87-92

Articles

Morphine and cancer progression: Hydrogen peroxide points to need for more research
Herbert Bosshart, MD
PDF
93-96
Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system
Kenneth Todd Moore, MS, Holly D. Adams, MS, Jaya Natarajan, PhD, Jay Ariyawansa, MS, Henry M. Richards, MD
PDF
99-107
Primary care physician opinion survey on FDA Opioid Risk Evaluation and Mitigation Strategies
Kieran A. Slevin, MD, Michael A. Ashburn, MD, MPH
PDF
109-115
Determination of medication cutoff values in a pain patient population
Amadeo Pesce, PhD, DABCC, Cameron West, PhD, Robert West, MS, Bridgit Crews, PhD, Charles Mikel, PhD, Murray Rosenthal, DO, FAPA, Perla Almazon, MT(ASCP), Sergey Latyshev, MS
PDF
117-122
Select practice behaviors of clinicians on the use of opioids for adolescents with subacute and chronic nonmalignant pain
John M. Saroyan, MD, Wendy Y. Cheng, MPH, Damani C. Taylor, BA, Amna Afzal, MD, Nomita Sonty, MPhil, PhD, Maria A. Sullivan, MD, PhD
PDF
123-134
Do transdermal opioids reduce healthcare use in an Australian rural pain population? A comparison with oral opioids
John S. Henshaw, MBBS, MMed, FANZCA, FFPMANZCA
PDF
135-144

Case Studies

The endocrine effects of long-term oral opioid therapy: A case report and review of the literature
Jennifer A. Elliott, MD, Erica Horton, DO, Eugene E. Fibuch, MD
PDF
145-154
Torsades-de-Pointes associated with Taku-Tsubo cardiomyopathy following greatly reduced oxycodone use in an elderly woman
Harry W. Daniell, MD
PDF
155-159

Full Issue

March/April 2011
 
PDF
81-160